Astrana Health, Inc. (ASTH) Form 8-K — Aug 6, 2026

$ASTHForm 8-KItems 2.02, 7.01, 9.01Filed Aug 6, 2026, 4:11 PM ET0001104659-26-092003Original filing

Astrana Health reported second quarter 2026 revenue of $972.5 million, up 49% year over year, with net income attributable to Astrana of $19.7 million, up 109%, diluted EPS of $0.40, and adjusted EBITDA of $68.9 million, up 43%. Adjusted diluted EPS came in at $0.80, up 45%, which management called a record high. First-half momentum was equally strong, with revenue up 52% to $1,937.6 million, adjusted diluted EPS of $1.54, operating cash flow of $100.8 million, and free cash flow of $92.9 million.

Key figures

Eps: $0.40 diluted (Q2 2026), up 111% from $0.19; $0.69 diluted (six months 2026)
Revenue: $972.5 million (Q2 2026); $1,937.6 million (six months 2026)
Guidance: FY2026 revenue $3,800-$4,100 million (reaffirmed); FY2026 adjusted EBITDA raised to $255-$280 million; FY2026 free cash flow $105-$132.5 million (reaffirmed); Q3 2026 revenue $1,000-$1,030 million and adjusted EBITDA $72.5-$77.5 million
Net Income: $19.7 million attributable to Astrana (Q2 2026), up 109%; $34.2 million (six months 2026), up 112%
Total Debt: $936.5 million ($53.8 million current portion + $882.7 million long-term)
Revenue Yoy: +49% (Q2 2026); +52% (six months 2026)
Total Assets: $2,282.1 million
Cash Position: $400.8 million (June 30, 2026)
Shares Outstanding: 49226943
Free Cash Flow: $92.9 million (six months 2026) vs $103.0 million prior year
Adjusted EBITDA: $68.9 million (Q2 2026), up 43% YoY; $135.2 million (six months), up 60% YoY
Interest Expense Q2: $16.0 million vs $7.4 million prior-year quarter
Operating Cash Flow: $100.8 million (six months 2026)
Adjusted EPSDiluted: $0.80 (Q2 2026), up 45%; $1.54 (six months), up 59%
Providers Supported: more than 20,000
Care Partners Revenue: $932.8 million (Q2 2026), up 48%
Gross Shared Savings2024: $120.4 million from affiliated ACOs
Patients In Value Based Care: approximately 1.5 million
Care Delivery Operating Loss: -$3.0 million (Q2 2026), down 238% YoY
Medicare Advantage Lives Added: approximately 3,000 via new Texas agreement

Price after filing

1 day: +0.4%7 days: +5.9%30 days: +7.8%

Close on the filing date to close N calendar days later (from $35.67). Historical, not a forecast.

AI analysis

Red flags5 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.